These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 11909981)

  • 1. Neuroprotection and dopamine agonists.
    Schapira AH
    Neurology; 2002 Feb; 58(4 Suppl 1):S9-18. PubMed ID: 11909981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonists and neuroprotection in Parkinson's disease.
    Olanow CW; Jenner P; Brooks D
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S167-74. PubMed ID: 9749590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of dopamine agonists in the treatment of early Parkinson's disease.
    Olanow CW
    Neurology; 2002 Feb; 58(4 Suppl 1):S33-41. PubMed ID: 11909983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
    Jenner P
    Neurology; 2002 Feb; 58(4 Suppl 1):S1-8. PubMed ID: 11909980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine agonists and neuroprotection in Parkinson's disease.
    Schapira AH
    Eur J Neurol; 2002 Nov; 9 Suppl 3():7-14. PubMed ID: 12464116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of dopamine agonists in early Parkinson's disease.
    Watts RL
    Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.
    Kitamura Y; Taniguchi T; Shimohama S; Akaike A; Nomura Y
    Neurochem Res; 2003 Jul; 28(7):1035-40. PubMed ID: 12737528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for dopamine agonist use as monotherapy in Parkinson's disease.
    Schwarz J
    Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S27-33. PubMed ID: 15180135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do dopamine agonists provide neuroprotection?
    Yamamoto M
    Neurology; 1998 Aug; 51(2 Suppl 2):S10-2. PubMed ID: 9711974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective, anti-apoptotic effects of apomorphine.
    Kyriazis M
    J Anti Aging Med; 2003; 6(1):21-8. PubMed ID: 12941180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Parkinson's disease: what is the best approach to treatment.
    Hristova AH; Koller WC
    Drugs Aging; 2000 Sep; 17(3):165-81. PubMed ID: 11043817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-apoptotic effect of modified Chunsimyeolda-tang, a traditional Korean herbal formula, on MPTP-induced neuronal cell death in a Parkinson's disease mouse model.
    Li H; Park G; Bae N; Kim J; Oh MS; Yang HO
    J Ethnopharmacol; 2015 Dec; 176():336-44. PubMed ID: 26593210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotection by dopamine agonists.
    Lange KW; Rausch WD; Gsell W; Naumann M; Oestreicher E; Riederer P
    J Neural Transm Suppl; 1994; 43():183-201. PubMed ID: 7884400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attempts to obtain neuroprotection in Parkinson's disease.
    Olanow CW
    Neurology; 1997 Jul; 49(1 Suppl 1):S26-33. PubMed ID: 9222272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole].
    Kohno Y; Takeuchi S
    Nihon Yakurigaku Zasshi; 2004 Jun; 123(6):429-40. PubMed ID: 15170083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease.
    Lewis MM; Huang X; Nichols DE; Mailman RB
    CNS Neurol Disord Drug Targets; 2006 Jun; 5(3):345-53. PubMed ID: 16787233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of early Parkinson's disease.
    Koller WC
    Neurology; 2002 Feb; 58(4 Suppl 1):S79-86. PubMed ID: 11909989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.